Johnson & Johnson presented results at the American College of Cardiology 24 on XARELTO® (rivaroxaban). These results show a reduction in the risk of clinically significant bleeding and adverse clinical events.

A new exploratory analysis demonstrates the consistent results of XARELTO® in the treatment of patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention.

XARELTO® is one of the most studied oral anticoagulants and has been prescribed to more than 10 million patients in the United States.

Despite advances in cardiovascular care, patients with non-valvular AF continue to be at risk of life-threatening cardiovascular events, particularly older patients who are considered difficult to treat due to multiple factors, including age and co-morbidities', said C. Michael Gibson*, M.D., DG of the non-profit Baim Institute and Professor of Medicine at Harvard Medical School.

Copyright (c) 2024 CercleFinance.com. All rights reserved.